<DOC>
	<DOC>NCT00607048</DOC>
	<brief_summary>This is a dose-finding study; therefore, there is no hypothesis testing</brief_summary>
	<brief_title>Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with metastatic solid tumors, for whom carboplatin and paclitaxel are appropriate; Patients &gt;18 years of age; Good performance status; Adequate bone marrow and organ function Previous treatment with any other compound that targets CD40 Current or planned concurrent treatment with any anticancer agent; Patients who have received bone marrow transplant; History of autoimmune disorder History (within the previous year) of heart failure or heart attack Cancerassociated coagulation disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>